Search
Aurothioglucose
go.drugbank.com/drugs/DB09121ApprovedWithdrawnContemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis [A32326].
Pimecrolimus
go.drugbank.com/drugs/DB00337ApprovedInvestigationalIt is currently available as a topic cream used in the treatment of atopic dermatitis (eczema). … Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.
Categories: Analgesics, Non-NarcoticTildrakizumab
go.drugbank.com/drugs/DB14004ApprovedInvestigationalMarch 2018. … A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257].
Eflapegrastim
go.drugbank.com/drugs/DB15001ApprovedInvestigationalin which the patient develops an infection during a period of significant neutropenia. … chemotherapy-induced neutropenia, including FN.
Ribociclib
go.drugbank.com/drugs/DB11730ApprovedInvestigationalRibociclib was approved by the FDA in March 2017 under the brand name Kisqali.
Pegilodecakin
go.drugbank.com/drugs/DB15162InvestigationalPegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small
Synonyms: INTERLEUKIN 10 (SYNTHETIC HUMAN), DIMER, N-TERMINAL 5-KILODALTON PEGYLATEDBone Marrow Suppression caused by Chemotherapy
go.drugbank.com/conditions/DBCOND0137031Drugs: TrilaciclibSynonyms: Bone Marrow Suppression caused by ChemotherapyBinimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigational[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients … with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.
CoviGlobulin
go.drugbank.com/drugs/DB15747ExperimentalDifferent antibodies have different mechanisms of action depending on their target. … The antibodies themselves are produced in response to an immunogen and derived from antibody-producing plasma cells that were once B-cell clones.